Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
Brian A BergmarkNicholas A MarstonThomas A ProhaskaVeronica J AlexanderAndré ZimermanFilipe A MouraSabina A MurphyErica L GoodrichShuanglu ZhangDaniel GaudetEwa Karwatowska-ProkopczukSotirios TsimikasRobert P GiuglianoMarc S Sabatinenull nullPublished in: The New England journal of medicine (2024)
In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, NCT05355402.).